-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 22, Zhejiang Medicine issued an announcement stating that the company had recently received the "Drug Registration Certificate" for levofloxacin sodium chloride injection 150ml: 0.
Levofloxacin is a quinolone antibiotic and is suitable for respiratory infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections, sepsis and other infections caused by sensitive bacteria
Levofloxacin was first listed in Japan by Daiichi Sankyo in 1993.
The company submitted a drug registration application (domestic production) to the State Drug Administration on November 29, 2019 and was accepted
The company issued an announcement on June 22, 2021 that Levofloxacin Sodium Chloride Injection 100ml:0.